Trial Profile
A Multicenter, Randomized Phase ll Study of Letrozole Versus Letrozole Plus Everolimus for Hormone Receptor-PositivePremenopausal Women With Recurrent or Metastatic Breast Cancer on Goserelin Treatment After Progression on Tamoxifen
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Sep 2023
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Letrozole
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms MIRACLE
- 14 Dec 2019 Primary endpoint has been met. (Progression free survival)
- 14 Dec 2019 Status changed from not yet recruiting to completed, according to results presented at the 42nd Annual San Antonio Breast Cancer Symposium
- 14 Dec 2019 Results assessing use of everolimus plus letrozole in advanced premenopausal breast cancer patients presented at the 42nd Annual San Antonio Breast Cancer Symposium